AN ACT relating to coverage for epinephrine devices.
Summary
HB236 requires health benefit plans in Kentucky to cover at least two medically necessary epinephrine devices for covered persons and limits annual cost sharing for that coverage to $100, except where doing so would interfere with a high-deductible health plan’s federal tax status. The bill defines “epinephrine device” as a single-use device that delivers a premeasured dose of epinephrine, which is commonly used to treat severe allergic reactions. The new coverage mandate is set to apply to health benefit plans issued or renewed on or after January 1, 2026.
The bill also makes conforming changes to several Kentucky statutes governing insurance, Medicaid, KCHIP, state employee health coverage, and postsecondary institution health plans so that those programs must include the new epinephrine-device coverage requirement. It adds the mandate to Medicaid-related coverage provisions, the Kentucky Children’s Health Insurance Program, state university self-insured plans, and the state employee health insurance program. The bill further includes procedures for federal compliance, including directions to seek waivers or approvals if needed and to report those requests to the Legislative Research Commission.
Impact
HB236 amends multiple sections of Kentucky law in KRS Chapters 205, 304, and 18A to add a new insurance coverage requirement for epinephrine devices across private health benefit plans and several public coverage programs. It creates a new statutory mandate in Subtitle 17A of KRS Chapter 304, then cross-references that mandate into Medicaid, KCHIP, state postsecondary employee plans, and the state-sponsored public employee health insurance program. The bill also establishes implementation dates, federal-law safeguards, and administrative duties for the Department of Insurance, the Department for Medicaid Services, and the Cabinet for Health and Family Services.
Sentiment
The available voting history shows strong support for the bill in the House, where it passed third reading 88-0. No committee transcript was provided, so there is no recorded floor or committee debate to indicate organized opposition in the materials supplied. Overall, the bill appears to have been viewed favorably as a health coverage measure intended to improve access to a life-saving medication delivery device.
Contention
The main policy issue embedded in the bill is cost and federal compliance. The bill limits annual cost sharing for the required epinephrine-device coverage, but it also includes exceptions for health savings account-qualified high-deductible health plans if the mandate would otherwise jeopardize federal tax treatment. It further anticipates that some provisions may require federal waivers or state plan amendments for Medicaid or exchange plans, and it directs agencies to seek those approvals before full implementation. Because the bill extends the mandate into multiple public insurance programs, any concern would likely center on premium impacts, administrative complexity, and whether the state must make cost-defrayal payments for exchange plans.